Mucin as a therapeutic target in pseudomyxoma peritonei

J Surg Oncol. 2012 Dec;106(7):911-7. doi: 10.1002/jso.23146. Epub 2012 May 14.


Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy?

Publication types

  • Review

MeSH terms

  • Goblet Cells / physiology
  • Humans
  • Mucins / physiology*
  • Peritoneal Neoplasms / etiology*
  • Peritoneal Neoplasms / pathology*
  • Peritoneal Neoplasms / therapy
  • Pseudomyxoma Peritonei / etiology*
  • Pseudomyxoma Peritonei / pathology*
  • Pseudomyxoma Peritonei / therapy
  • Signal Transduction / physiology


  • Mucins